ASAP — Asarina Pharma AB (publ) Income Statement
0.000.00%
Last trade - 00:00
- SEK20.42m
- SEK18.26m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | SAS | SAS | SAS | SAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | -2.83 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 81 | 81.4 | 38.3 | 14.7 | 14.7 |
Operating Profit | -81 | -81.4 | -38.3 | -14.7 | -14.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -78.9 | -83 | -38.3 | -14.8 | -14.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -71.1 | -75.3 | -31.7 | -13.3 | -12.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -71.1 | -75.3 | -31.7 | -13.3 | -12.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -71.1 | -75.3 | -31.7 | -13.3 | -12.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.85 | -4.08 | -1.69 | -0.707 | -0.57 |
Dividends per Share |